Subjective sensations after intravitreal injection of bevacizumab;Subjektives empfinden nach intravitrealer bevacizumab-injektion

Klinische Monatsblatter fur Augenheilkunde

Volumn 224, Issue 3, 2007, Pages 180-184

  Ach, Thomas ^a   Dawczynski, J ^a   Konigsdorffer E ^a   Augsten, R ^a   Strobel, J ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Age related macular degeneration; AMD; Avastin; Bevacizumab; Intravitreal injection; Subjective sensations

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; FOLLOW UP; HUMAN; METAMORPHOSIS; OPTICAL COHERENCE TOMOGRAPHY; RATING SCALE; RETINA BLOOD VESSEL OCCLUSION; RETINA DETACHMENT; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; SENSATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MACULAR EDEMA, CYSTOID; MALE; MIDDLE AGED; PATIENT SATISFACTION; SENSATION; SENSATION DISORDERS; TREATMENT OUTCOME; VISION DISORDERS; VISUAL ACUITY;

EID: 34248387290     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963035     Document Type: Article

References (16)

1. Avery RL et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372
2. Avery RL et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 133: 1695
3. Aktualisiertes Konsenspapier der Retinologischen Gesellschaft der Deutschen Ophthalmologischen Gesellschaft. Stellungnahme zu ak tuellen therapeutischen Möglichkeiten bei der neovaskularen alters abhängigen Makuladegeneration. Klin Monatsbl Augenheilkd 2006; 223: 271-278
4. Bashshur ZF et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1-9
5. Brody BL et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108: 1893-1900
6. Costa RA et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. IOVS 2006; 47: 4569-4578
7. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-1349
8. Iturralde D et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006; 26: 279-284
9. Jonas JB et al. Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration. Eur J Ophthal 2006; 16: 774-775
10. Jaissle GB, Szurman P, Bartz-Schmidt KU. Empfehlung für die Durchführung von intravitrealen Injektionen. Klin Monatsbl Augenheilkd 2005; 222: 390-395
11. rd LO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthal 2006; 142: 685-688
12. Michels S. Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 2006; 90: 1333-1334
13. Rich RM et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511
14. Rovner BW et al. Minimal depression and vision function in age-related macular degeneration. Ophthalmology 2006; 113: 1743-1747
15. Spaide RF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390
16. Völcker M et al. Früher antioxidativer Effekt - OCT-Monitoring nach intravitrealer Bevacizumab-Applikation. Ophthalmologe 2006; 103: 476-483